Chemistry:Arcarine
From HandWiki
Arcarine (ORM-11984) is a selective androgen receptor modulator (SARM) developed by Orion Corporation, a Finnish pharmaceutical company.[1][2][3] It belongs to a class of drugs designed to have tissue-selective androgenic effects, potentially offering the benefits of androgens while minimizing unwanted side effects.[1] Arcarine was investigated for the treatment of various conditions, including benign prostatic hyperplasia, hypogonadism, and osteoporosis.[4][5] The compound reached Phase I clinical trials before development was discontinued.[4] Like other SARMs, Arcarine was developed to potentially provide anabolic effects in muscle and bone tissue while having reduced androgenic effects in other tissues, such as the prostate.[4]
References
- ↑ 1.0 1.1 "Local delivery of a selective androgen receptor modulator failed as an anabolic agent in a rat bone marrow ablation model". Acta Orthopaedica 86 (6): 751–9. 2015. doi:10.3109/17453674.2015.1074840. PMID 26198725.
- ↑ "Research programme: selective androgen receptor modulators (Alternative Names: Arcarine; ORM-11984)". 4 November 2017. https://adisinsight.springer.com/drugs/800024357.
- ↑ "Delving into the Latest Updates on Arcarine with Synapse". 13 October 2024. https://synapse.patsnap.com/drug/3c0a1cb1cbc14552b622c39a85ef56fd.
- ↑ 4.0 4.1 4.2 "Arcarine". Synapse. PatSnap. https://synapse.patsnap.com/drug/3c0a1cb1cbc14552b622c39a85ef56fd.
- ↑ "Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021)". European Journal of Medicinal Chemistry 230. February 2022. doi:10.1016/j.ejmech.2022.114119. PMID 35063736.
 |  |
